Meda's acquisition of Recip is concluded

Meda's acquisition of Recip is concluded

Meda's acquisition of Recip AB was announced on 25 October 2007. The acquisition
is now concluded. Meda receives product rights and brands, rights to the name
Recip, and it takes over existing sales operations. The organisation has around
50 persons; most of them are in marketing and sales. The product portfolio
consists of well-established pharmaceuticals such as Kåvepenin®, Heracillin®,
Kalcipos®, and TrioBe®. The acquisition strengthens Meda's home base in Sweden,
and new product opportunities from Recip's product portfolio can be
commercialised outside the Nordics. Considerable synergy effects can also be
achieved.

The acquisition price for all shares in Recip AB was SEK 2,650 million on a
debt-free basis plus SEK 5.7 million newly issued shares in Meda AB. The net
debt that Meda took over totaled SEK 832 million. Meda's cash payment was thus
SEK 1,818 million, totally financed within existing credit facilities. The price
for the newly issued shares was set at SEK 86.25 per share.



For more information, please contact Meda:
Anders Larnholt, Investor Relations	tel. +46 709 458 878

MEDA AB (publ) is an international specialty pharma company that concentrates on
marketing and market-adapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda is
represented with own organisations in 26 countries and with more than 1 500
employees within marketing and sales. Meda's products are sold in approximately
120 countries world-wide. The Meda share is listed under Large Cap on the OMX
Nordic Stock Exchange. Find out more, visit www.meda.se.